Home / People / Dr. Imme Kley
Portrait ofImme Kley

Dr. Imme Kley

Counsel
Rechtsanwältin

CMS Hasche Sigle
Stadthausbrücke 1-3
20355 Hamburg
Germany
Languages German, English, French

As an expert for the life sciences, agrosciences and commercial sectors, Imme Kley mainly advises pharmaceutical companies, medical device manufacturers, agroscience companies as well as companies in related regulated industries. She regularly assists her clients with drafting and negotiating cooperation and development or distribution agreements for business development purposes. She furthermore focuses on product liability law as well as on statutory health insurance law issues, in particular in the context of new forms of care, and on crop protection law. She also represents her clients in contentious cases. Imme also regularly advises in transactions in the life sciences sector.

Before joining CMS in 2013, Imme worked as management consultant at McKinsey & Company. She has been a counsel since 2021.

more less

Publications

  • Die Vergabe sogenannter nachrangiger Dienstleistungsaufträge: Begriff, materielle Vorgaben, Verfahren, Rechtsschutz, Peter Lang, 2010
more less

Education

  • 2011: Second state examination in law
  • 2010: PhD on a Stiftung der Deutschen Wirtschaft (foundation set up by German industry associations) scholarship; thesis on procurement law
  • 2009 - 2011: Trainee lawyer, including placements at a major law and the Consulate General of the Federal Republic of Germany in Ho Chi Minh City, Vietnam
  • 2006 - 2009: Research assistant to Prof. Dr. Hermann Pünder at Bucerius Law School, Hamburg
  • 2006: First state examination in law
  • Law studies at the Bucerius Law School and Université Paris I Panthéon-Sorbonne
more less

Feed

01/08/2014
CMS advises Almirall on multi-billion acquisition of respiratory disease...
Hamburg – Internationally active pharmaceutical firm Almirall S.A. (Barcelona) has agreed with London-based AstraZeneca plc to transfer its drug platform for respiratory disease treatments. Once the...
01/08/2014
CMS advises Almirall on multi-billion acquisition of respiratory disease...
Hamburg – Internationally active pharmaceutical firm Almirall S.A. (Barcelona) has agreed with London-based AstraZeneca plc to transfer its drug platform for respiratory disease treatments. Once the...